Lv51
1360 积分 2023-09-01 加入
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
11天前
已完结
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
11天前
已完结
Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients with Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia
15天前
已完结
Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development
17天前
已完结
Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients with Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia
17天前
已完结
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial
18天前
已完结
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
22天前
已完结
Ligelizumab for Chronic Spontaneous Urticaria
2个月前
已完结
Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis
2个月前
已完结
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
2个月前
已完结
皖公网安备34019202002308
